GlassScriptPhysician profile
Joseph Mangel
NPI 1093759409
$3,096.81
in general payments reported to CMS, 2019-2025
22 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $201 · 2021: $234 · 2022: $28.17 · 2023: $375 · 2024: $242 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,104.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $472.52 | 2019-2025 | |
| Lilly USA, LLC | $208.12 | 2023-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.99 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $150.37 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $115.08 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.66 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.05 | 2019 | |
| Pfizer INC. | $107.96 | 2019 | |
| Amarin Pharma, INC. | $102.34 | 2019-2020 | |
| Astellas Pharma US INC | $94.15 | 2019-2020 | |
| Genentech USA, INC. | $61.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $56.46 | 2019 | |
| Merck Sharp & Dohme LLC | $49.73 | 2019 | |
| Kerecis Limited | $43.28 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $39.66 | 2019 | |
| Concordia Pharmaceuticals INC. | $27.62 | 2019 | |
| Allergan, INC. | $25.79 | 2019 | |
| Verona Pharma, INC. | $17.00 | 2025 | Ohtuvayre |
| Amgen INC. | $15.54 | 2019 | |
| Zyla Life Sciences, INC. | $13.97 | 2019 | |
| Novo Nordisk INC | $13.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mangel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.